Strategies and developments of immunotherapies in osteosarcoma (Review)
- Authors:
- Jia Wan
- Xianghong Zhang
- Tang Liu
- Xiangsheng Zhang
-
Affiliations: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China - Published online on: November 24, 2015 https://doi.org/10.3892/ol.2015.3962
- Pages: 511-520
This article is mentioned in:
Abstract
|
Sakamoto A and Iwamoto Y: Current status and perspectives regarding the treatment of osteo-sarcoma: Chemotherapy. Rev Recent Clin Trials. 3:228–231. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mori K, Rédini F, Gouin F, Cherrier B and Heymann D: Osteosarcoma: Current status of immunotherapy and future trends (Review). Oncol Rep. 15:693–700. 2006.PubMed/NCBI | |
|
Loeb DM: Is there a role for immunotherapy in osteosarcoma? Cancer Treat Res. 152:447–457. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Habel N, Hamidouche Z, Girault I, Patiño-García A, Lecanda F, Marie PJ and Fromigué O: Zinc chelation: A metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance. Cell Death Dis. 4:e8742013. View Article : Google Scholar : PubMed/NCBI | |
|
Wilky BA and Goldberg JM: Immunotherapy in sarcoma: A new frontier. Discov Med. 17:201–206. 2014.PubMed/NCBI | |
|
D'Angelo SP, Tap WD, Schwartz GK and Carvajal RD: Sarcoma immunotherapy: Past approaches and future directions. Sarcoma. 2014:3919672014. View Article : Google Scholar : PubMed/NCBI | |
|
Russell SJ, Peng KW and Bell JC: Oncolytic virotherapy. Nat Biotechnol. 30:658–670. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Dzierzbicka K, Gozdowska M and Kołodziejczyk AM: L-MTP-PE - a potential antineoplastic agent. Postepy Hig Med Dosw. 51:227–236. 1997.(In Polish). PubMed/NCBI | |
|
Kager L, Pötschger U and Bielack S: Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag. 6:279–286. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK and Howard PE: Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 81:935–938. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Kleinerman ES, Gano JB, Johnston DA, Benjamin RS and Jaffe N: Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 18:93–99. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF and Jaffe N: Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity and immune stimulation. J Immunother Emphasis Tumor Immunol. 17:181–193. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, et al: Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol. 26:633–638. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU 3rd, Nieder ML, Weiner MA, Wells RJ, et al: Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. Cancer. 115:5339–5348. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, et al: Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer. 61:238–244. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, et al: Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. J Exp Clin Cancer Res. 33:272014. View Article : Google Scholar : PubMed/NCBI | |
|
Song HJ, Lee EK, Lee JA, Kim HL and Jang KW: The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: A Markov model analysis. Tumour Biol. 35:8771–8779. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lindner DJ: Interferons as antiangiogenic agents. Curr Oncol Rep. 4:510–514. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S and Bernstein M: The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer. 54:350–354. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Müller CR, Smeland S, Bauer HC, Saeter G and Strander H: Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncol. 44:475–480. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Strander H and Einhorn S: Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer. 19:468–473. 1977. View Article : Google Scholar : PubMed/NCBI | |
|
Brosjö O, Bauer HC, Broström LA, Nilsonne U, Nilsson OS, Reinholt FP, Strander H and Tribukait B: Influence of human alpha-interferon on four human osteosarcoma xenografts in nude mice. Cancer Res. 45:5598–5602. 1985.PubMed/NCBI | |
|
Manara MC, Serra M, Benini S, Picci P and Scotlandi K: Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol. 24:365–372. 2004.PubMed/NCBI | |
|
Strander H, Bauer HC, Brosjö O, Fernberg JO, Kreicbergs A, Nilsonne U, Silfverswärd C, Signomklao T and Söderlund V: Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol. 34:877–880. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK and Tendler CL: Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol. 20:3841–3849. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM and Statkevich P: Treating cancer with PEG Intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 95:389–396. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Postiglione L, Di Domenico G, Giordano-Lanza G, Ladogana P, Turano M, Castaldo C, Di Meglio F, Cocozza S and Montagnani S: Effect of human granulocyte macrophage-colony stimulating factor on differentiation and apoptosis of the human osteosarcoma cell line SaOS-2. Eur J Histochem. 47:309–316. 2003.PubMed/NCBI | |
|
Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA, Smithson WA, Burch P, Gornet M and Rahman E: Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res. 5:2316–2323. 1999.PubMed/NCBI | |
|
Arndt CA, Koshkina NV, Inwards CY, et al: Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: Effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group. Clin Cancer Res. 16:4024–4030. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Du T, Shi G, Li YM, Zhang JF, Tian HW, Wei YQ, Deng H and Yu DC: Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 21:340–348. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schwinger W, Klass V, Benesch M, Lackner H, Dornbusch HJ, Sovinz P, Moser A, Schwantzer G and Urban C: Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol. 16:1199–1206. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Luksch R, Perotti D, Cefalo G, Gambacorti Passerini C, Massimino M, Spreafico F, Casanova M, Ferrari A, Terenziani M, Polastri D, et al: Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori. 89:263–268. 2003.PubMed/NCBI | |
|
Guma SR, Lee DA, Ling Y, Gordon N and Kleinerman ES: Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer. 61:1362–1368. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, Wang WL and Kleinerman ES: Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer. 61:618–626. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kohyama K, Sugiura H, Kozawa E, Wasa J, Yamada K, Nishioka A, Kamei Y and Taguchi O: Antitumor activity of an interleukin-2 monoclonal antibody in a murine osteosarcoma transplantation model. Anticancer Res. 32:779–782. 2012.PubMed/NCBI | |
|
Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F and Liggitt D: Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther. 16:937–946. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME: Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
DeRenzo C and Gottschalk S: Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol. 804:323–340. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ruella M and Kalos M: Adoptive immunotherapy for cancer. Immunol Rev. 257:14–38. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Restifo NP, Dudley ME and Rosenberg SA: Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol. 12:269–281. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314:126–129. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, et al: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 114:535–546. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenberg SA: Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol. 8:577–585. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 29:917–924. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, et al: Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36:133–151. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, et al: Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 122:863–871. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, et al: T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 19:620–626. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Song DG, Ye Q, Poussin M, Harms GM, Figini M and Powell DJ Jr: CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 119:696–706. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Maher J, Brentjens RJ, Gunset G, Rivière I and Sadelain M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 20:70–75. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Altvater B, Landmeier S, Pscherer S, Temme J, Juergens H, Pule M and Rossig C: 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. Cancer Immunol Immunother. 58:1991–2001. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G and Powell DJ Jr: In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71:4617–4627. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hombach AA, Heiders J, Foppe M, Chmielewski M and Abken H: OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 1:458–466. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X and Ferrone S: HLA class I antigen down-regulation in primary ovary carcinoma lesions: Association with disease stage. Clin Cancer Res. 11:67–72. 2005.PubMed/NCBI | |
|
Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA and Healey JH: Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res. 382:59–65. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, et al: Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 17:1779–1787. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM and Ahmed N: Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 19:212–217. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Huang G, Yu L, Cooper LJ, Hollomon M, Huls H and Kleinerman ES: Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 72:271–281. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kiessling S, Muller-Newen G, Leeb SN, Hausmann M, Rath HC, Strater J, Spottl T, Schlottmann K, Grossmann J, Montero-Julian FA, et al: Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. J Biol Chem. 279:10304–10315. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH and Darcy PK: Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 19:5636–5646. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Raulet DH and Guerra N: Oncogenic stress sensed by the immune system: Role of natural killer cell receptors. Nat Rev Immunol. 9:568–580. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ljunggren HG and Kärre K: In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 11:237–244. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Markiewicz K, Zeman K, Kozar A, Gołębiowska-Wawrzyniak M and Woźniak W: Evaluation of selected parameters of cellular immunity in children with osteosarcoma at diagnosis. Med Wieku Rozwoj. 16:212–221. 2012.PubMed/NCBI | |
|
Moore C, Eslin D, Levy A, Roberson J, Giusti V and Sutphin R: Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer. 55:1096–1102. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Delgado D, Webster DE, DeSantes KB, Durkin ET and Shaaban AF: KIR receptor-ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells. Pediatr Blood Cancer. 55:1300–1305. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, et al: Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 97:1374–1380. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H and Campana D: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 16:3901–3909. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pahl JH, Ruslan SE, Buddingh EP, et al: Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res. 18:432–441. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tam YK, Martinson JA, Doligosa K and Klingemann HG: Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy. 5:259–272. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG and Bug G: Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 15:1563–1570. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K and Campana D: A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 73:1777–1786. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dillman R, Barth N, Selvan S, Beutel L, de Leon C, DePriest C, Peterson C and Nayak S: Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 19:581–588. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mackall CL, Rhee EH, Read EJ, et al: A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 14:4850–4858. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, et al: Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys. 82:924–932. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Suminoe A, Matsuzaki A, Hattori H, Koga Y and Hara T: Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatr Transplant. 6:746–753. 2009. View Article : Google Scholar | |
|
Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, Hale J, Douglas C, Pagonis C, Campbell B, et al: Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer. 92:1358–1365. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kawaguchi S, Tsukahara T, Ida K, Kimura S, Murase M, Kano M, Emori M, Nagoya S, Kaya M, Torigoe T, et al: SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group. Cancer Sci. 103:1625–1630. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Miki K, Nagaoka K, Harada M, Hayashi T, Jinguji H, Kato Y and Maekawa R: Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLs. Int Immunopharmacol. 23:499–504. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Geng P, Cai X and Wang J: Comprehensive evaluation of the cytotoxic T-lymphocyte antigen-4 gene polymorphisms in risk of bone sarcoma. Genet Test Mol Biomarkers. 18:574–579. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yano H, Thakur A, Tomaszewski EN, Choi M, Deol A and Lum LG: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med. 12:1912014. View Article : Google Scholar : PubMed/NCBI | |
|
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11:155–164. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D'Adamo DR, Keohan ML, Wagner MJ, Scheu K, Chiu R, Ritter E, et al: A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013:1681452013. View Article : Google Scholar : PubMed/NCBI | |
|
Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW and Lake RA: Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 8:e618952013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Wang J, Song H, Liu J, Song B and Cao X: Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 15:503–506. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, Song W and Yuan W: Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 30:1051–1055. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sznol M and Chen L: Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 19:1021–1034. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kline J and Gajewski TF: Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 11:1354–1359. 2010.PubMed/NCBI | |
|
Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, et al: Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol. 35:741–749. 2009.PubMed/NCBI | |
|
Iwai Y, Terawaki S and Honjo T: PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 17:133–144. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, et al: Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 8:e828702013. View Article : Google Scholar : PubMed/NCBI | |
|
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics and immunologic correlates. J Clin Oncol. 28:3167–3175. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng W, Xiao H, Liu H and Zhou Y: Expression of programmed death 1 is correlated with progression of osteosarcoma. APMIS. 123:102–107. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lynch JP 3rd, Fishbein M and Echavarria M: Adenovirus. Semin Respir Crit Care Med. 32:494–511. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tomko RP, Xu R and Philipson L: HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA. 94:3352–3356. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Chu RL, Post DE, Khuri FR and Van Meir EG: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res. 10:5299–5312. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Liu TC and Kirn D: Viruses with deletions in antiapoptotic genes as potential oncolytic agents. Oncogene. 24:6069–6079. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:373–376. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, et al: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 6:798–806. 2000.PubMed/NCBI | |
|
Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B and Koeffler HP: Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 50:7950–7954. 1990.PubMed/NCBI | |
|
Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK and Kyritsis AP: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 19:2–12. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Witlox AM, Van Beusechem VW, Molenaar B, Bras H, Schaap GR, Alemany R, Curiel DT, Pinedo HM, Wuisman PI and Gerritsen WR: Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin Cancer Res. 10:61–67. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez-Velez N, Xipell E, Jauregui P, Zalacain M, Marrodan L, Zandueta C, Vera B, Urquiza L, Sierrasesúmaga L, Julián MS, et al: The oncolytic adenovirus ∆24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity. J Bone Miner Res. 29:2287–2296. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, Todoroki T, Tanaka N, Hamada H and Yokoyama KK: E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res. 63:4434–4440. 2003.PubMed/NCBI | |
|
Fukuda K, Abei M, Ugai H, Kawashima R, Seo E, Wakayama M, Murata T, Endo S, Hamada H, Hyodo I and Yokoyama KK: E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer Gene Ther. 16:126–136. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Benjamin R, Helman L, Meyers P and Reaman G: A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther. 12:1591–1593. 2001.PubMed/NCBI | |
|
Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner TA and Kao C: Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis. J Gene Med. 8:679–689. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer. 33:787–791. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Li G, Kawashima H, Ogose A, Ariizumi T, Xu Y, Hotta T, Urata Y, Fujiwara T and Endo N: Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus. J Cancer Res Clin Oncol. 137:1037–1051. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xie YF, Sheng W, Xiang J, Zhang H, Ye Z and Yang J: Adenovirus-mediated ING4 expression suppresses pancreatic carcinoma cell growth via induction of cell-cycle alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer Biother Radiopharm. 24:261–269. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xu M, Xie Y, Sheng W, Miao J and Yang J: Adenovirus-mediated ING4 gene transfer in osteosarcoma suppresses tumor growth via induction of apoptosis and inhibition of tumor angiogenesis. Technol Cancer Res Treat. 14:369–378. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Miranda CA, Lima EG, de Lima DB, Cobucci RN, Cornetta Mda C, Fernandes TA, de Azevedo PR, de Azevedo JC, de Araújo JM and Fernandes JV: Genital infection with herpes simplex virus types 1 and 2 in women from natal, Brazil. ISRN Obstet Gynecol. 2014:3236572014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Dai M, You L and Zhao Y: Advance in herpes simplex viruses for cancer therapy. Sci China Life Sci. 56:298–305. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hingorani P, Sampson V, Lettieri C and Kolb EA: Oncolytic viruses for potential osteosarcoma therapy. Adv Exp Med Biol. 804:259–283. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Smith KD, Mezhir JJ, Bickenbach K, Veerapong J, Charron J, Posner MC, Roizman B and Weichselbaum RR: Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol. 80:1110–1120. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kelly KJ, Wong J and Fong Y: Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs. 17:1105–1113. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kroeger KM, Muhammad AK, Baker GJ, Assi H, Wibowo MK, Xiong W, Yagiz K, Candolfi M, Lowenstein PR and Castro MG: Gene therapy and virotherapy: Novel therapeutic approaches for brain tumors. Discov Med. 10:293–304. 2010.PubMed/NCBI | |
|
Bharatan NS, Currier MA and Cripe TP: Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hematol Oncol. 24:447–453. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
He S, Li P, Chen CH, Bakst RL, Chernichenko N, Yu YA, Chen N, Szalay AA, Yu Z, Fong Y and Wong RJ: Effective oncolytic vaccinia therapy for human sarcomas. J Surg Res. 175:e53–e60. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pollack SM, Loggers ET, Rodler ET, Yee C and Jones RL: Immune-based therapies for sarcoma. Sarcoma. 2011:4389402011. View Article : Google Scholar : PubMed/NCBI |
